Covaxin clinical trials in children between 2-18 years to begin in 10-12 Days: Centre
Team Udayavani, May 19, 2021, 10:09 AM IST
New Delhi: Days after the Drugs Controller General of India (DCGI) accorded its approval for Phase 2-3 clinical trials of Bharat Biotech’s Covaxin for children aged between 2-18 years, Niti Aayog Member (Health) Dr. VK Paul on Tuesday informed that the trials will begin in the next 10-12 days
Addressing the media Dr Paul, who is also chairman of the government task force on Covid-19 said, “COVAXIN has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days.”
As part of the second phase of the trial, 525 ‘healthy subjects’ will be administered two doses of the Covaxin vaccine at an interval of 28 days- on day 0 and day 28 through ‘intramuscular route’, as per the release by the Government of India.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
INDIA bloc seeking JPC probe into Adani ‘scam’, govt scared of debate: Congress after LS, RS adjourned
Youth Congress demands Adani’s arrest over USD 250 mn bribery charge
RG Kar protests: SC orders SIT probe into custodial torture case, weekly reports before HC
Burglars decamp with cash Rs 1 crore, 300 gold sovereigns from house in Kerala
No ‘formula’ under discussion for CM’s post: Ajit Pawar
MUST WATCH
Latest Additions
INDIA bloc seeking JPC probe into Adani ‘scam’, govt scared of debate: Congress after LS, RS adjourned
Ranbir on criticism for doing ‘Sanju’, ‘Animal’: Important to dabble in different genres, characters
Youth Congress demands Adani’s arrest over USD 250 mn bribery charge
Study links overthinking to ‘constant communication’ between brain’s fear-centre, social behaviour
Sometimes I like to take backseat and do films where pressure is not on me: Taapsee Pannu
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.